SOPHiA GENETICS SA (NASDAQ:SOPH) Q1 2024 Earnings Call Transcript

In that sense, I would say the fact that today, in the context of the partnership we have with MSK and AstraZeneca, we’ve been able in the prelaunch of this application to sign nine customers in almost all continents around the world. It’s a very, very strong sign of the quality of the application. When it comes to the ASP, it’s significantly much higher ASP because it’s a solution that is more sophisticated. And so indirectly, our average ASP will benefit as well from that as we were getting traction and utilization, which is something we expect to happen again from Q3, Q4 of this year.

Vivian Bais: Great. Thanks so much for taking the questions.

Jurgi Camblong: Thank you, Vivian.

Operator: And ladies and gentlemen, with that, we’re showing no additional questions. We’ll end today’s question-and-answer session. I’d like to turn the floor back over to management for any closing remarks.

Jurgi Camblong: Yes. So, thank you all for joining us today. Next week, we will be on Tuesday, New York at the RBC Conference. To end, I would like to basically recap our Q1 performance. So we recognize that revenue was lighter than what we had expected, but business momentum is really good, both on the pipeline and bookings side. And something that we didn’t highlight in the Q&A is that our cost performance and loss performance have significantly improved as well. And as Ross said, we continue to be committed to sustainable growth and reach our pass-through profitability in the next two-plus years. With that, thank you very much, and have a good day.

Operator: Ladies and gentlemen, with that, we’ll be concluding today’s conference call and presentation. We do thank you for joining. You may now disconnect your lines.

Jurgi Camblong: Thank you.